TLR4 and neoplasm: Furthermore, tumor-bearing mice and clinicopathology were used to verify that the LMW-HA/TLR4/CXCR7 pathway may be critical during the development of PTC, indicating LMW-HA as a possible novel immunomodulatory therapy target for PTC treatment.